10x Genomics, Inc.
Close on Oct 19, 2026
- Market cap
- $9.08B
- P/E (TTM)
- –
- Dividend yield
- –
About 10x Genomics
Laboratory Analytical Instruments, SIC 3826
10x Genomics, Inc. is a life sciences technology company that develops integrated solutions to interrogate and analyze biological systems. Its product portfolio spans instruments, consumables, and software across single-cell analysis and spatial biology platforms. The single-cell offering, anchored by the Chromium system, partitions samples into barcoded components for high-throughput multiomic readouts. The spatial biology portfolio features the Visium and Xenium platforms, which enable tissue-scale spatial transcriptomics and in situ optical imaging of gene expression without conventional sequencing. A complementary software ecosystem, including pipeline and visualization tools, supports experimental planning, data processing, and analysis. The company primarily serves academic, government, biotechnology, and biopharmaceutical research institutions.
The company operates globally, selling its products in more than 50 countries through direct sales organizations and third-party distribution partners. It maintains certified manufacturing operations across facilities in Pleasanton, California, Singapore, and Taiwan, while outsourcing instrument assembly to qualified contract manufacturers. The company employs over 1,100 personnel across research, commercial, and operational functions. Its principal executive offices are located in Pleasanton, California.
Summary of the business section of 10x Genomics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- 10x Genomics, Inc.
- Founded
- 2012
- Headquarters
- Pleasanton, CA
- Address
- 6230 Stoneridge Mall Road 94588
- Phone
- (925) 401-7300
- Website
- 10xgenomics.com
- Employees
- 1,178, Dec 31, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Jose, California
Stock & identifiers
- Ticker
- TXG
- Exchange
- Nasdaq
- IPO date
- Sep 12, 2019
- Shares outstanding
- 130M, Jul 31, 2026
- Public float
- $1.30B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1770787
- CUSIP
- 88025U109
- ISIN
- US88025U1097
- LEI
- 5493003Z6741WNLG7H43
- EIN
- 45-5614458
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Serge Saxonov | Chief Executive Officer, Director | 4,153,758 |
| Benjamin J. Hindson | See Remarks, Director | 3,621,682 |
| Adam Taich | Chief Financial Officer | 330,098 |
| Shehnaaz Suliman | Director | 23,792 |
| John R. Stuelpnagel | Director | 785,725 |
| Sarah A. Teichmann | Director | 28,058 |
| Kimberly J. Popovits | Director | 37,445 |
| Alan Mateo | Director | 85,877 |
| Sridhar Kosaraju | Director | 68,278 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Serge Saxonov | $6.33M | $6.79M | $2.76M | $12 | $125 |
| FY2024 Serge Saxonov | $7.93M | -$21.17M | $4.40M | $10 | $93 |
| FY2023 Serge Saxonov | $8.29M | $17.35M | $3.40M | $40 | $94 |
| FY2022 Serge Saxonov | $18.81M | -$14.31M | $9.38M | $26 | $90 |
| FY2021 Serge Saxonov | $11.70M | $20.81M | $4.98M | $105 | $100 |
| FY2020 Serge Saxonov | $10.88M | $55.28M | $6.51M | $186 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed a total of 1,178 individuals, 822 of whom were employed in the United States and 356 of whom were employed outside the United States.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 13, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 12, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 6, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |